Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.17826 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: Is targeting TIGIT an answer?
Esophagus
January 2025
Department of Medical Oncology, National Taiwan University Cancer Center, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Esophageal squamous cell carcinoma (ESCC) is a prevalent and highly lethal malignancy in Asia. Recent advancements in immune checkpoint inhibitors (ICIs) have markedly transformed the systemic therapy landscape for ESCC. Anti-PD-1-based combination with chemotherapy or with ipilimumab, an anti-CTLA-4 antibody, have been established as the new standard first-line treatments for patients with advanced ESCC.
View Article and Find Full Text PDFIs it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?
Oncologist
January 2025
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Whether preoperative chemoradiotherapy (CRT) or perioperative chemotherapy is superior for localized esophageal or gastro-esophageal junction (GEJ) cancers has been a topic of long-standing debate. For years, standard of care in the United States for localized esophageal or GEJ adenocarcinoma (EAC) has been physician's choice between the 2 strategies. More recently, adjuvant immunotherapy has also been introduced into the treatment approach for those who received neoadjuvant CRT.
View Article and Find Full Text PDFPrognostic value of immunosuppression scores in patients with esophageal squamous cell carcinoma: a multicenter study.
Front Immunol
January 2025
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Introduction: The prognostic impact of human leukocyte antigen-E (HLA-E) expression and the proportion of natural killer (NK) cells in esophageal squamous cell carcinoma (ESCC) was investigated.
Methods: This study retrospectively evaluated 397 ESCC patients across two centers. The cumulative incidence of recurrence (CIR) and the incidence of tumor-related death (CID) were analyzed in various groups.
A Case of Radical Resection of Esophageal Basaloid Cell Carcinoma After Hemostasis by Transarterial Embolization.
Case Rep Surg
January 2025
Department of Surgery, Ise Red Cross Hospital, 1-471-2 Funae, Ise City, Mie, Japan.
Esophageal bleeding management typically involves endoscopy but becomes challenging with large or hemorrhagic tumors, especially in cases of rare basal cell carcinoma. This malignancy, with a poorer prognosis than squamous cell carcinoma, often requires definitive surgery. A 78-year-old man with severe hematemesis underwent transarterial embolization (TAE) after failed endoscopic hemostasis for a middle thoracic esophageal tumor.
View Article and Find Full Text PDFPurine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers.
Mol Med
January 2025
Nanjing Women and Children's Healthcare Hospital, Maternal and Child Health Institute, Women's Hospital of Nanjing Medical University, 123 Tianfei Alley, Mochou Road, Nanjing, China.
Proteins that bind to DNA/RNA are typically evolutionarily conserved with multiple regulatory functions in transcription initiation, mRNA translation, stability of RNAs, and RNA splicing. Therefore, dysregulation of DNA/RNA binding proteins such as purine-rich element binding protein alpha (PURα) disrupts signaling transduction and often leads to human diseases including cancer. PURα was initially recognized as a tumor suppressor in acute myeloid leukemia (AML) and prostate cancer (PC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!